Home
Resources
Publications
Targeting MMP-9 in Diabetic Foot Ulcers

Targeting MMP-9 in Diabetic Foot Ulcers

Jeffrey I Jones, Trung T Nguyen, Zhihong Peng, Mayland Chang

Pharmaceuticals (Basel). 2019 May 22;12(2):79.

PMID: 31121851

Abstract:

Diabetic foot ulcers (DFUs) are significant complications of diabetes and an unmet medical need. Matrix metalloproteinases (MMPs) play important roles in the pathology of wounds and in the wound healing process. However, because of the challenge in distinguishing active MMPs from the two catalytically inactive forms of MMPs and the clinical failure of broad-spectrum MMP inhibitors in cancer, MMPs have not been a target for treatment of DFUs until recently. This review covers the discovery of active MMP-9 as the biochemical culprit in the recalcitrance of diabetic wounds to healing and targeting this proteinase as a novel approach for the treatment of DFUs. Active MMP-8 and MMP-9 were observed in mouse and human diabetic wounds using a batimastat affinity resin and proteomics. MMP-9 was shown to play a detrimental role in diabetic wound healing, whereas MMP-8 was beneficial. A new class of selective MMP-9 inhibitors shows clinical promise for the treatment of DFUs.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP130370604-A	Batimastat		130370-60-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: